Your browser doesn't support javascript.
loading
Evaluation of late effects during a 21-year follow-up of pediatric Hodgkin lymphoma survivors: Experience of a pediatric cancer center in Turkey, as a developing country model.
Tacyildiz, Nurdan; Cakmak, Hatice M; Unal, Emel; Dincaslan, Handan; Tanyildiz, Gulsah; Özdemir, Sonay I; Kartal, Ömer; Yilmaz, Yasin; Yavuz, Gulsan; Kuzu, Isinsu.
Afiliação
  • Tacyildiz N; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Cakmak HM; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Unal E; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Dincaslan H; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Tanyildiz G; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Özdemir SI; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Kartal Ö; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Gülhane Training and Research Hospital, Ankara /Turkey.
  • Yilmaz Y; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Yavuz G; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara /Turkey.
  • Kuzu I; Department of Patology, Ankara University Faculty of Medicine,Ankara /Turkey.
Indian J Cancer ; 2024 Jan 09.
Article em En | MEDLINE | ID: mdl-38195683
ABSTRACT

BACKGROUND:

Long-term survivors of Hodgkin lymphoma (HL) are at risk of developing a range of late effects, with a second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The present study aims to evaluate the late side effects in children with HL. MATERIALS AND

METHODS:

Out of 53 HL patients, we assessed the long-term effects of childhood HL survivors (HLSs; n = 50) diagnosed between 1998 and 2019. Patient data related to chronic health conditions, and sociodemographic characteristics were compared with their siblings (n = 56).

RESULTS:

The cumulative overall survival (OS) at 1, 5, and 10 years from diagnosis was 98.1 ± 1.9%, 93.3 ± 3.8%, and 93.3 ± 3.8%, respectively. Groups of HLSs and their siblings were matched according to age and gender. Compared with siblings, survivors had will be changed as 'a higher frequency of nephrotoxicity (P = 0.02)', cardiotoxicity (P = 0.12), thyroid dysfunction (P = 0.001), health care service usage (P < 0.01), limitation of physical function (P = 0.01), and pulmonary disease (P = 0.01). The control group of siblings had a higher incidence of marital status (P < 0.01), parenthood (P = 0.01), and smoking habit (P = 0.03). Thyroid dysfunction was associated with neck radiotherapy (P < 0.01). No secondaryneoplasm was detected. In relapsed, refractory setting (n = 10), autologous transplantation (n = 9) is performed after a complete remission. Brentuximab vedotin with or without bendamustine and rituximab is also used in selected patients.

CONCLUSIONS:

Increased number of chronic health conditions and social problems point to the significance of long-term follow-up of HLSs. We are currently preparing a survivorship guideline appropriate for Turkey's conditions. IMPLICATIONS FOR CANCER SURVIVORS Renal, heart, pulmonary impairment, thyroid dysfunction, limitation in physical functioning, and deterioration in social status (marriage, having children, education).

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article